1. de Mora F. Biosimilar: what it is not. Br J Clin Pharmacol. 2015;80:949–56.
2. EMA (European Medicines Agency). Guideline on similar biological medicinal products. In: Committee for Medicinal Products for Human Use (CHMP), CHMP/437/04 Rev 1. 2014.
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf
. Accessed 14 May 2019.
3. FDA (US Food and Drug Administration). Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. 2015.
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf
. Accessed 14 May 2019.
4. WHO (World Health Organization). Guidelines on evaluation of similar biotherapeutic products (SBPs). 2009.
http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf?ua=1
. Accessed 14 May 2019.
5. IMS. Delivering on the Potential of Biosimilar Medicines. 2016.
https://www.medicinesforeurope.com/wp-content/uploads/2016/03/IMS-Institute-Biosimilar-Report-March-2016-FINAL.pdf
. Accessed 14 May 2019.